Vol 11, Supp. K (2015)
Case report
Published online: 2016-04-24
Gefitinib as a first line therapy in a patient with non small cell lung cancer STRESZCZENIE
Abstract
A case report of a 65-year-old woman who received gefitinib as a first line therapy for adenocarcinoma of the lung between March 2013 and October 2014 at Oncology Centre M. Sklodowska-Curie Memorial Institute in Warsaw. The patient was diagnosed as clinical stage IV (both lung metastasis). The treatment was well tolerated. The clinical and radiological benefits of EGFR-tyrosine kinase inhibitor (TKI) have been observed in the above patient with EGFR mutation.
Keywords: gefitinibfirst line therapynon small cell lung cancer